Inhibition of Polo-like kinase 1 (PLK1) synergizes with Vemurafenib in the treatment of melanoma.

(A and B) Immunoblots of cleaved-PARP (c-PARP) and p-ERK detected in A375 (A) and A375R (B) cells after 48 h treatment of either DMSO, Vemurafenib, Volasertib, or a combination of Vemurafenib and Volasertib, respectively. (C–E) Percentages of apoptotic...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Fengyi Mao (15073242) (author)
Άλλοι συγγραφείς:	Sai Wu (6096290) (author), Derek B. Allison (15141675) (author), Daheng He (9189701) (author), Yifan Kong (4458616) (author), Chaohao Li (15141681) (author), Zhiguo Li (431917) (author), Yanquan Zhang (14930570) (author), Xinyi Wang (559030) (author), Qiongsi Zhang (2818111) (author), Chi Wang (131921) (author), Xiaoqi Liu (45630) (author)
Έκδοση:	2025
Θέματα:	Cell Biology Genetics Molecular Biology Developmental Biology Cancer Hematology Biological Sciences not elsewhere classified suppress tumor growth like kinase 1 crucial transcription factor cnc homolog 1 clinical database analysis shortened mice survival >< sup >< div >< p cutaneous melanoma based v600e </ sup patient survival pten </ ca </ ></ sup synergistic efficiency novel function negatively correlates genes involved cell cycle cancer progression cancer metabolism bach1 ), >- deficiency
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Inhibition of Polo-like kinase 1 (PLK1) synergizes with Vemurafenib in the treatment of melanoma.

Παρόμοια τεκμήρια